Semax & Selank: The Neuropeptides On Every Watchlist

Two compact neuropeptides out of Russian research programmes, studied for cognition and for stress. Here is why they stay on every watchlist.

Small, Fast, Targeted

Semax and Selank are compact peptides originally developed in Russian research programmes. Their small size lets researchers study specific brain-signalling pathways with unusual precision. Where a large protein interacts with many systems at once, a short, well-defined peptide can be aimed at a narrower question, which makes cause and effect easier to isolate.

Both are synthetic sequences built on fragments of naturally occurring molecules. Semax is derived from a short region of ACTH, a hormone involved in the body’s stress and signalling systems, with a small structural modification that makes it more stable. Selank is based on a fragment of tuftsin, a peptide linked to immune and regulatory signalling. In each case the design goal is the same: take a biologically meaningful sequence and turn it into something stable enough to study reliably.

For labs mapping neuro-signalling, a well-characterised short peptide is a valuable, low-noise tool.

Where They Are Studied

Semax features in cognition, attention and neuroprotection research. A recurring theme in the literature is its studied relationship with BDNF, a signalling protein tied to how neurons grow and adapt, which is one reason it keeps surfacing in work on learning and neural resilience. As with any research peptide, the story is about pathways, not promises.

Selank is studied more in anxiety- and stress-response models. Its research profile is often discussed in relation to the regulatory systems that modulate mood and arousal, and it is of interest partly because it is investigated as a way to probe those pathways without the sedative profile associated with some other approaches. Again, the value to a researcher is the mechanism, not any claim about outcomes.

Part of what makes both compounds attractive as tools is their route and stability profile. Short peptides of this kind are often studied via intranasal delivery in the research literature, and the small structural tweaks built into each sequence are designed to slow how quickly the peptide is broken down. For a researcher, a compound that is stable and reaches its target reliably is a compound that produces cleaner, more repeatable data, which is precisely the quality that earns a place on a watchlist.

Two Peptides, Two Questions

It is worth keeping the pair distinct. They are often mentioned together because they share an origin and a format, but they point at different research questions. Semax leans toward the cognitive and neuroprotective; Selank toward stress and regulation. Treating them as one thing blurs exactly the specificity that makes each useful on the bench.

Why The Interest Endures

Reproducibility and a clean mechanism keep them on watchlists. For labs mapping neuro-signalling, a well-characterised short peptide is a valuable, low-noise tool. When a compound behaves consistently and engages a defined pathway, it becomes a dependable instrument for asking harder questions, rather than a variable that has to be controlled for.

That said, much of the human research sits in older or regionally concentrated literature, and independent replication at modern scale is still building. The honest reading is that both are interesting, mechanistically specific and well worth watching, while remaining research compounds rather than settled answers.

Where ONE% Fits

Semax and Selank are not part of the ONE% core range. We cover them as peptides to watch, alongside other compounds generating genuine research interest beyond what we stock and test ourselves. For the wider landscape, our roundup of peptides to watch sets them in context, and our how peptides work explainer covers why short peptides make such precise research tools.

Because these two sit outside our tested catalogue, the most useful standard we can offer is what documented quality looks like. Everything in our range is third-party tested and batch-referenced to a Certificate of Analysis, so identity and purity are demonstrated rather than assumed. Our lab testing page sets out that process, and the ONE% range shows the compounds we supply to it. Whatever the peptide, and whoever the supplier, the principle holds: ask for the analytical data. With short neuropeptides in particular, where sequence modifications are subtle and purity is easy to overstate, documented identity is what separates a reliable research input from an unknown one.

Frequently Asked Questions